Subsequent Neoplasm Risk After Modern Mediastinal Radiation Therapy for Pediatric Hodgkin Lymphoma: Insights From a Multi-Institutional Children’s Oncology Group Trial

Milgrom SA, Paganetti H, Dama H, Renfro L, Wu Y, Meyer I, Jeeva M, Parsons SK, Punnett A, Charpentier AM, Lo AC, Vega RM, Keller FG, Kelly KM, Hoppe BS, Castellino SM, Hodgson D. Subsequent Neoplasm Risk After Modern Mediastinal Radiation Therapy for Pediatric Hodgkin Lymphoma: Insights From a Multi-Institutional Children’s Oncology Group Trial. Int J Radiat Oncol Biol Phys. 2026 Feb 6:S0360-3016(26)00361-5. doi: 10.1016/j.ijrobp.2026.01.026. Epub ahead of print. PMID: 41655816; PMCID: PMC13089109.

The reported incidence of subsequent malignant neoplasms (SMN) in long-term survivors of pediatric classic Hodgkin lymphoma (cHL) is based on patients treated with outdated radiation therapy (RT) doses and techniques. The risk associated with modern mediastinal RT in pediatric cHL is unknown. We modeled the risk of SMN in children with cHL who enrolled in the multi-institutional Children’s Oncology Group AHOD1331 trial (2015–2019) and received mediastinal RT.